Don't break up: The Tipline for 1 May 2019

Some believe the era of bipartisanship on Capitol Hill ended a long time ago. But those people clearly forget about the bonding powers of pharmaceutical-related antitrust legislation. The House Judiciary Committee cleared four bills related to competition in the drug industry yesterday with representatives from both sides of the aisle taking turns to praise the legislation. Meanwhile, FTC commissioner Noah Phillips said he is unconvinced that breaking up companies – rather than issuing behavioural remedies – is a better solution to address monopolistic practices in the technology sector.

Get unlimited access to all Global Competition Review content